How about Model Based Drug Development? I think population PK has heped in understanding the PK of compounds in patient population. Even with few plasma samples, one can get estimates of population parameters like Clearance, Volume of distribution and the effect of covariates like age, weight, genotypes across various studies. I totally agree with you on the impact of “omics” in drug discovery and development!

Thanks for the post on drug intercations. I think you hit the nail with the example of CYP3A4 induction by St. Johns wort. Rifampin, known as prototypical CYP3A4 inducer has been contraindicated for coadministration with several drugs like statins, some of the protease inhibitors etc. Often one can notice in the drug label that grape fruit juice should be avoided during the intake of a specific medication. This is because of its CYP3A4 inhibition potential, thereby increasing the plasma concentrations of co administered drug and causing un wanted adverse events. Drug interactions gets even complicated when the same drub is an inducer or inhibitor of transporters lik PgP or OATP. With new transporters emerging every now and then, I wonder how one would go about evaluating drug interactions. Any thoughts?